Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 known ✓ | P11229 | 19/20 | 0.71 |
| ▸ | CHRM3 known ✓ | P20309 | 19/20 | 0.71 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 19/20 | 0.71 |
| ▸ | BCHE | P06276 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL1925665 | 1.00 | CHRM2 (0.71) | CHRM2CHRM1CHRM3BCHEACHE | |
| SCHEMBL1924969 | 0.99 | CHRM2 (0.72) | CHRM2CHRM1CHRM3 | |
| SCHEMBL1924968 | 0.99 | CHRM2 (0.72) | CHRM2CHRM1CHRM3 | |
| Iodide SCHEMBL4094583 | 0.93 | CHRM2 (0.65) | CHRM2CHRM1CHRM3BCHEACHE | |
| SCHEMBL2832071 | 0.88 | CHRM2 (0.67) | CHRM2CHRM1CHRM3 | |
| SCHEMBL2832610 | 0.87 | CHRM2 (0.71) | CHRM2CHRM1CHRM3 | |
| SCHEMBL2832609 | 0.87 | CHRM2 (0.64) | CHRM2CHRM1CHRM3 | |
| Iodide SCHEMBL1925324 | 0.87 | CHRM2 (0.56) | CHRM2CHRM1CHRM3BCHEACHE | |
| Iodide SCHEMBL1925322 | 0.87 | CHRM2 (0.56) | CHRM2CHRM1CHRM3BCHEACHE | |
| Iodide SCHEMBL1924832 | 0.86 | CHRM2 (0.55) | CHRM2CHRM1CHRM3BCHEACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1300407-B2 | CARBAMATES DERIVED FROM ARYLALKYLAMINES | S A L V A T LAB SA (ES) | 2011-06-08 | — | — | EP | claimed |
| US-7435742-B2 | Quinuclidine derivatives and pharmaceutical compositions containing the same | LABORATORIOS ALMIRALL S.A. (ES) | 2008-10-14 | — | — | US | claimed |
| US-20060094751-A1 | Quinuclidine derivatives and pharmaceutical compositions containing the same | ALMIRALL, S.A. (ES) | 2006-05-04 | — | — | US | claimed |
| EP-1300407-B2 | CARBAMATES DERIVED FROM ARYLALKYLAMINES | S A L V A T LAB SA (ES) | 2011-06-08 | — | — | EP | disclosed |
| US-20090054480-A1 | NOVEL QUINUCLIDINE CARBAMATE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | LABORATORIOS ALMIRALL S.A. | 2009-02-26 | — | — | US | disclosed |
| US-20090005412-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | LABORATORIOS ALMIRALL S.A. | 2009-01-01 | — | — | US | disclosed |
| US-7435742-B2 | Quinuclidine derivatives and pharmaceutical compositions containing the same | LABORATORIOS ALMIRALL S.A. (ES) | 2008-10-14 | — | — | US | disclosed |
| US-20060094751-A1 | Quinuclidine derivatives and pharmaceutical compositions containing the same | ALMIRALL, S.A. (ES) | 2006-05-04 | — | — | US | disclosed |
| US-6916828-B2 | Carbamates derivatived from arylakylamines | LABORATORIOS S.A.L.V.A.T., S.A. (ES) | 2005-07-12 | — | — | US | disclosed |
| EP-1515968-A2 | QUINUCLIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | Almirall Prodesfarma AG (CH) | 2005-03-23 | — | — | EP | disclosed |
| US-20040063950-A1 | Carbamates derivatived from arylakylamines | LABORATORIOS S.A.L.V.A.T., S.A. (ES) | 2004-04-01 | — | — | US | disclosed |
| EP-1300407-B1 | CARBAMATES DERIVED FROM ARYLALKYLAMINES | S A L V A T LAB SA (ES) | 2004-02-25 | — | — | EP | disclosed |
| WO-2004000840-A2 | QUINUCLIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | ALMIRALL PRODESFARMA AG (CH) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005412-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | CHRM3, CHRM2, CHRM1 | CHRM1 3/4885CHRM3 1/4885ACHE 22/4885 |
| US-20060094751-A1 | Quinuclidine derivatives and pharmaceutical compositions containing the same | CHRM3, CHRM2, CHRM1 | CHRM1 3/4885CHRM3 1/4885ACHE 20/4885 |
| US-20040063950-A1 | Carbamates derivatived from arylakylamines | CHRM3, CHRM2, CHRM1 | CHRM1 3/4885CHRM3 1/4885ACHE 508/4885 |
| US-20090054480-A1 | NOVEL QUINUCLIDINE CARBAMATE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | CHRM3, CHRM2, CHRM1 | CHRM1 3/4885CHRM3 1/4885ACHE 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.